This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SAN DIEGO and NEW YORK,
May 17, 2013 /PRNewswire/ --
Shareholder rights attorneys at Robbins Arroyo LLP announce that a shareholder of Ventrus Biosciences, Inc. (NASDAQ: VTUS) filed a federal securities fraud class action complaint on
May 9, 2013, in the U.S. District Court for the Southern District of New York. The complaint alleges that Ventrus and certain of its officers and directors violated the Securities Exchange Act of 1934 between
December 17, 2010 and
June 25, 2012 (the "Class Period"). Ventrus is a pharmaceutical company that specializes in the development and commercialization of late-stage prescription drugs for gastrointestinal disorders.
Ventrus Accused of Making False and Misleading Statements Concerning the Company's Lead Product, Iferanserin VEN 309
According to the complaint, Ventrus and certain of its officers and directors, made materially false and misleading statements during the Class Period and failed to disclose material adverse facts about the company's lead product, iferanserin
VEN 309, a topical treatment for symptomatic internal hemorrhoids. Specifically, the complaint alleges that Ventrus falsely represented that: (i) iferanserin
VEN 309 was a one-of-a-kind product that had no competing FDA approved comparisons; (ii) iferanserin
VEN 309 would be the only product approved for use as a prescription treatment for hemorrhoids; (iii) the prior phase II and IIB studies of iferanserin
VEN 309 demonstrated a consistent reduction of hemorrhoidal symptoms; (iv) the company had the ability to market iferanserin
VEN 309 to 12.5 million potential patients; and (v) the Phase III of the trial of iferanserin
VEN 309 was low risk in comparison to other therapeutic drug development programs.
The complaint also alleges that Ventrus touted its communications with the Federal Drug Administration as frequent and ongoing as evidence that FDA approval for iferanserinVEN 309 would be achieved. Moreover, the company's misrepresentations of iferanserin
VEN 309 allowed Ventrus to raise over
$70 million through its
December 17, 2010 initial public offering and a subsequent offering approximately one month prior to disclosing the truth to its shareholders.
The Truth Is Revealed and Ventrus' Stock Price Drops
June 25, 2012, Ventrus issued a press release announcing that iferanserin
VEN 309 failed its Phase III trial. Additionally, Ventrus disclosed that it would abandon further development of iferanserin
VEN 309 and would no longer attempt to obtain FDA approval. In response to this news, Ventrus' stock plunged over 50%, to close at
$5.02 per share on
June 25, 2012.
If you purchased or otherwise acquired Ventrus stock during the Class Period and wish to serve as lead plaintiff, you must act no later than
July 8, 2013. To discuss your
shareholder rights, please contact attorney
Darnell R. Donahue at (800) 350-6003,
email@example.com, or via the
shareholder information form on the firm's website.
Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than
$1 billion of value for themselves and the companies in which they have invested. For more information, please go to
Press release link:
Attorney Advertising. Past results do not guarantee a similar outcome.